Intravitreal Ranibizumab versus Thermal Laser Photocoagulation in the Treatment of Extrafoveal Classic Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

被引:9
|
作者
Ladas, Ioannis D. [1 ]
Chatziralli, Irini P. [1 ]
Kotsolis, Athanasios I. [1 ]
Douvali, Maria [2 ]
Georgalas, Ilias [1 ]
Theodossiadis, Panagiotis G. [2 ]
Rouvas, Alexandros A. [2 ]
机构
[1] Univ Athens, Med Sch Athens, Dept Ophthalmol 1, Athens, Greece
[2] Univ Athens, Med Sch Athens, Dept Ophthalmol 2, Athens, Greece
关键词
Age-related macular degeneration; Extrafoveal choroidal neovascularization; Ranibizumab; Thermal laser; VERTEPORFIN PHOTODYNAMIC THERAPY; SUBGROUP ANALYSIS; JUXTAFOVEAL; MARINA;
D O I
10.1159/000337347
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background: To compare the efficacy of thermal laser photocoagulation versus intravitreal ranibizumab for the treatment of extrafoveal classic choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Methods: We conducted a retrospective study on 24 eyes with extrafoveal classic CNV secondary to AMD, treated either with thermal laser photocoagulation (group 1) or with intravitreal ranibizumab (group 2). Visual acuity, number of injections/sessions and recurrence rate were assessed. Results: The mean follow-up time was 23.6 +/- 2.26 and 19.1 +/- 9.74 months for group 1 and 2, respectively. Mean best corrected visual acuity (BCVA) of groups 1 and 2 was 0.59 +/- 0.32 and 0.46 +/- 0.30 logMAR, respectively (p = 0.343). At the end of the follow-up, mean BCVA of group 1 was 0.92 +/- 0.35 and of group 20.16 +/- 0.12 logMAR and differed statistically compared to baseline (p = 0.02 and p = 0.006, respectively). There was a statistically significant difference between the two groups as far as BCVA at the end of the follow-up was concerned (p < 0.0001). The patients in group 1 received on average 1.38 sessions of thermal laser photocoagulation, while patients in group 2 received on average 4 injections of ranibizumab. The recurrence rate in the laser group was 84.6%, while in the ranibizumab group it was 18.2% (p < 0.001). Specifically, the mean time of recurrence in the laser group was 11.5 months, whereas in the ranibizumab group it was 18 months (p = 0.048). Conclusion: Intravitreal ranibizumab showed promising results in BCVA improvement and decrease in macular thickness in patients with extrafoveal classic CNV due to AMD, with a small number of injections. Laser photocoagulation treatment presented worsening in BCVA and high recurrence rate in our study with long-term follow-up. Copyright (C) 2012 S. Karger AG, Basel
引用
收藏
页码:93 / 101
页数:9
相关论文
共 50 条
  • [21] Indirect scatter laser photocoagulation to subfoveal choroidal neovascularization in age-related macular degeneration
    Jennifer Arnold
    Michel Algan
    Gisèle Soubrane
    Gabriel Coscas
    Emmanuel Barreau
    Graefe's Archive for Clinical and Experimental Ophthalmology, 1997, 235 : 208 - 216
  • [22] Sequential combined therapy for treatment of choroidal neovascularization in age-related macular degeneration: Photodynamic therapy and thermal laser photocoagulation
    Ruiz-Moreno, JM
    Montero, JA
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2003, 13 (08) : 681 - 686
  • [23] Indirect scatter laser photocoagulation to subfoveal choroidal neovascularization in age-related macular degeneration
    Arnold, J
    Algan, M
    Soubrane, G
    Coscas, G
    Barreau, E
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 1997, 235 (04) : 208 - 216
  • [24] INDIRECT PHOTOCOAGULATION OF SUBFOVEAL CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION
    ANGIOLETTI, LV
    COLQUHOUN, PJ
    KULIK, AD
    MALPICA, EH
    BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE, 1991, 67 (04) : 389 - 398
  • [25] PERSISTENT AND RECURRENT NEOVASCULARIZATION AFTER LASER PHOTOCOAGULATION FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION OF AGE-RELATED MACULAR DEGENERATION
    MAGUIRE, MG
    KLEIN, ML
    OLK, J
    PHILLIPS, DA
    ALEXANDER, J
    JAVORNIK, NB
    HINER, C
    MARSH, MJ
    BRESSLER, NM
    SINGERMAN, LJ
    MATHENY, J
    BROWN, J
    ARCHIVES OF OPHTHALMOLOGY, 1994, 112 (04) : 489 - 499
  • [26] Occult with no classic choroidal neovascularization secondary to age-related macular degeneration treated by intravitreal triamcinolone and photodynamic therapy with verteporfin
    Nicolò, M
    Ghiglione, D
    Lai, S
    Nasciuti, F
    Cicinelli, S
    Calabria, G
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2006, 26 (01): : 58 - 64
  • [27] Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration
    Bashshur, Ziad F.
    Bazarbachi, Ali
    Schakal, Alexandre
    Haddad, Zeina A.
    El Haibi, Christelle P.
    Noureddin, Baha' N.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2006, 142 (01) : 1 - 9
  • [28] TUNABLE DYE-LASER PHOTOCOAGULATION FOR CHOROIDAL NEOVASCULARIZATION COMPLICATING AGE-RELATED MACULAR DEGENERATION
    SINGERMAN, LJ
    KALSKI, RS
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 1989, 9 (04): : 247 - 257
  • [29] ICGA-guided laser photocoagulation of occult choroidal neovascularization in age-related macular degeneration
    Brancato, R
    Introini, U
    Bolognesi, G
    Pacelli, G
    Trabucchi, G
    Pece, A
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2000, 20 (02): : 134 - 142
  • [30] Brachytherapy - Optional treatment for choroidal neovascularization secondary to age-related macular degeneration
    Saric, B
    Sikic, J
    Katusic, D
    Vukojevic, N
    COLLEGIUM ANTROPOLOGICUM, 2001, 25 : 89 - 96